219 results about "Drug Dissolution" patented technology

The doxylamine succinate pyridoxine enteric-coated tablet comprises a tablet core and a coating layer, the coating layer comprises a first isolation layer, an enteric-coated layer and a second isolation layer, the materials of the enteric-coated layer comprise a plasticizer, an anti-sticking agent, a defoaming agent and a flexible coating material, and the flexible coating material accounts for 24-28% of the mass of the tablet core. By adding the flexible coating material, the stability of the pharmaceutical preparation is improved, the difference between batches is reduced, the drug dissolution rate reaches 90% or above, and the pharmaceutical preparation can be quickly released.

The present invention discloses an intelligent preparation device for tumor chemotherapy drugs, which relates to the technical field of chemotherapy drug preparation, including a straight guide rail, an arc guide rail, a vertical slider installed on the straight guide rail, and an arc slider installed on the arc guide rail. A rotating motor is fixedly provided on the upper surface of the arc slider, a preparation table is fixedly provided at the output end of the rotating motor, and a placement rack for placing medicine bottles is provided at equal angles on the edge of the preparation table. A rotating shaft is fixedly provided in the middle of both sides of the multiple placement racks, and one end of the rotating shaft is rotatably connected to the preparation table. The present invention extracts the liquid medicine in the bottle by simulating the manual side hole needle syringe drug extraction method, and injects the extracted liquid medicine into the bottle again, and repeats this process until the liquid medicine is completely dissolved. The extraction and injection are mechanically controlled to reduce bubbles, and the needle is attached to the side wall of the inclined medicine bottle, which reduces the generation of bubbles while allowing the liquid medicine in the medicine bottle to be completely extracted, thereby increasing the stability of drug dissolution, effectively protecting the operator, and improving the efficiency of tumor chemotherapy drug preparation.

The invention discloses a nano-drug delivery method for enhancing LGP kidney targeted release and application of the nano-drug delivery method, and relates to the technical field of nano-drugs. According to the nano-drug delivery method for enhancing LGP kidney targeted release and the application thereof, a hydrophobic modified chitosan polymer is synthesized; preparing HCS nanoparticles; and constructing a drug loaded nanoparticle, namely, HCS-LGP NPs. According to the invention, the solubility of the medicine is increased, the distribution of the medicine in vivo is changed, and the targeting of the medicine is improved, so that the treatment effect is improved, and adverse reactions are reduced. Due to good biocompatibility and modifiability, chitosan is widely used as a nano delivery carrier of anti-tumor and antibacterial drugs.

The invention belongs to the technical field of medicines, and discloses a meloxicam cataplasm and a preparation method thereof. The meloxicam cataplasm is composed of a backing layer, a paste layer and a protective layer, wherein the paste layer comprises an active component meloxicam, an adhesive, a humectant, a drug dissolution promoter, a transdermal enhancer, a surfactant, a pH regulator, a preservative and the balance of water for injection. The preparation method comprises the following steps: dissolving an adhesive, a transdermal enhancer and a preservative in water for injection, stirring and uniformly mixing to serve as a matrix phase; uniformly mixing the meloxicam with the humectant, adding the drug dissolution promoter and the surfactant to dissolve the active ingredients, and uniformly stirring to obtain a liquid medicine phase; the preparation method comprises the following steps: transferring a matrix phase and a liquid medicine phase into a closed vacuum tank, stirring and mixing in vacuum, adding a pH regulator, continuously stirring to obtain an ointment, uniformly coating a backing material with the ointment, covering the upper surface with a protective layer, and drying at low temperature to obtain the meloxicam cataplasm, which can relieve inflammation symptoms of soft tissue injury, such as pain, swelling and the like. The medicine is used for treating osteoarthritis.

The present invention belongs to the field of drug testing instruments, and relates to a drug dissolution tester and a calibration method thereof. The drug dissolution tester comprises a frame, a water bath, a dissolution cup, a stirring paddle and a driving mechanism. The dissolution cup is detachably mounted in a cup hole of the water bath. A calibration cover is placed on the cup mouth of the dissolution cup in a coaxial positioning manner. The surface layer of the calibration cover is a pressure-sensitive imaging layer. A calibration hole adapted to the paddle shaft of the stirring paddle is coaxially arranged in the center of the calibration cover. When the inverted paddle shaft is coaxial with the dissolution cup, the paddle shaft passes through the calibration hole and then extends into the dissolution cup. When the inverted paddle shaft is not coaxial with the dissolution cup, the paddle shaft cannot pass through the calibration hole, and the pressure-sensitive imaging layer of the calibration cover senses the paddle shaft and develops on the calibration cover to indicate the eccentric position of the paddle shaft. A fine-tuning mechanism is installed on the top plate of the water bath, which is used to fine-tune the position of the dissolution cup in the cup hole according to the development. The present invention can quickly calibrate the coaxiality of the paddle shaft and the dissolution cup.

The invention relates to the technical field of preparation of biological materials and pharmaceutical preparations, in particular to organic composite hydrogel as well as a preparation method and application thereof. The specific preparation method comprises the following steps: dissolving a targeted drug in orthoester to obtain a targeted drug-orthoester solution; the preparation method comprises the following steps: mixing an oxidized dextran solution, a targeted drug-orthoester solution and a carboxymethyl chitosan solution, carrying out vortex treatment, and standing to prepare the organic composite hydrogel. The solubility of the targeted drug in the hydrogel is improved by utilizing orthoester, the orthoester can carry the targeted drug to efficiently escape from the hydrogel, and the targeted drug can be self-assembled to form nanoparticles along with degradation of the orthoester in the escape process, so that the retention capacity of the targeted drug at a tumor site is enhanced, and the targeting drug can be used for treating tumor tumors. The drug enrichment capacity is improved, meanwhile, the toxic and side effects of the whole body are reduced, and the problems that nano-drugs are poor in solubility, still prone to being removed after intravenous administration and poor in enrichment effect at tumor sites are solved.

A closed-loop sampling system for drug dissolution by flow-through cell method and its use method, comprising a constant-temperature water bath system, a flow-through cell system, a lifting mechanism, a circulating heating system, a solvent monitoring system, a solvent circulation system and a sampling system; the constant-temperature water bath system includes a constant-temperature water bath frame, a constant-temperature water bath, a solvent cup holder, a solvent cup and a solvent cup cover; the flow-through cell system is arranged at the top of the constant-temperature water bath system; the lifting mechanism is arranged on one side of the constant-temperature water bath frame; the circulating heating system includes a heating device and a water circulation pump; the circulating inlet end of the solvent monitoring system is communicated with the heating device, and the circulating outlet end of the solvent monitoring system is respectively communicated with the solvent cup and the flow-through cell; the solvent circulation system includes a solvent circulation pump and a pulse valve; the sampling system includes a sampling mechanism, a sampling pipeline, a sampling valve and a sampling pump. The device of the present invention has a compact structure, high heating efficiency of the heating device, uniform water temperature distribution in the water bath, accurate water temperature control, and temperature and pressure monitoring of the solvent.

The invention belongs to the technical field of anhydrous emulsions, and discloses an anhydrous self-emulsifying drug-loaded emulsion based on a deep eutectic solvent and a preparation method thereof.The preparation method comprises the following steps that 1, betaine and a hydrogen bond donor are mixed, the deep eutectic solvent is prepared through a mixed heating method, a drug is dissolved in the deep eutectic solvent, and a drug solution is prepared; the hydrogen bond donor is levulinic acid or lactic acid; (2) mixing Tween 80 and Span 80 according to a mass ratio of (1-2): 1 to obtain a surfactant, adding absolute ethyl alcohol as a co-emulsifier, adding isopropyl myristate, and uniformly stirring and mixing to obtain a dispersion liquid; and (3) dropwise adding the drug solution in the step (1) into the dispersion liquid in the step (2), and stirring at the same time to finally form the anhydrous self-emulsifying drug-loaded emulsion. According to the invention, the loading capacity, the stability and the bioavailability of the medicine can be obviously improved; in addition, the efficiency of transdermal drug delivery of the emulsion is high, and the emulsion can be applied to skin external preparations.

The invention belongs to the field of medicine preparations, and particularly relates to a local external medicine composition for treating alopecia, the medicine composition comprises at least one active component, and the medicine composition comprises the following components in percentage by weight: 1-10% w / w of minoxidil or salt thereof, 0-50% w / w of propylene glycol, 1-50% w / w of ethanol and 10-50% w / w of C3-C10 ether solvent, the total dosage of the propylene glycol and the ethanol is less than or equal to 50% w / w, and the total dosage of the propylene glycol and the ethanol is less than or equal to 50% w / w. The pharmaceutical composition at least has the following excellent characteristics: good curative effect, high drug solubility, high patient efficiency, quick response, few adverse reactions, low scalp irritation, good stability, easy use, no greasy feeling after use, good drug permeability, high bioavailability, few use times, good patient compliance and the like.

The invention discloses an ionic liquid microemulsion and application thereof in an external preparation drug-loading matrix, and belongs to the field of pharmaceutical preparations, the microemulsion takes choline lactate ionic liquid or choline acetate as a hydrophilic phase and oleic acid as an oleophylic phase, and is supplemented with a mixed emulsifier; the mixed emulsifier is prepared by mixing polyoxyethylene 40 hydrogenated castor oil and diethylene glycol monoethyl ether according to the mass ratio of 3: 1-1: 3, the hydrophilic phase accounts for 10-30% by mass, the oleophylic phase accounts for 3-20% by mass, and the emulsifier accounts for 50-80% by mass, an ionic liquid micro-emulsion is constructed, the raw material medicine and the ionic liquid micro-emulsion are mixed, and the medicine carrying micro-emulsion preparation is obtained; the process is simple, the used ionic liquid is simple and easy to obtain, the requirement for equipment needed in the preparation process is low, and the obtained ionic liquid microemulsion can remarkably improve the solubility of insoluble drugs and promote the transdermal efficiency of the drugs and is suitable for being used as a drug carrying matrix of an external preparation.

The invention discloses a pH response hydrogel microneedle, which comprises a microneedle substrate, microneedle tips are arranged on the microneedle substrate, the height of the microneedle tips is 100-1600 microns, the diameter of the tip ends of the microneedle tips is 5-15 microns, and the density of the microneedle tips is 200-1000 pieces per square centimeter. The preparation method comprises the following steps: preparing a hyaluronic acid solution for the microneedle substrate, preparing a methacrylated chondroitin sulfate solution for the microneedle tip, preparing methacrylated orthoester, preparing orthoester, preparing a non-steroidal anti-inflammatory drug solution, preparing a microneedle tip solution, preparing the microneedle and demolding the microneedle to prepare the complete soluble microneedle patch. The invention has the advantages of high drug efficiency, high efficiency in dissolving fat / water drugs, and long-acting slow release.

The invention discloses a fluralan chewable tablet as well as a preparation method and application thereof, and belongs to the field of pharmaceutical preparations. The flurala chewable tablet disclosed by the invention comprises the following components in parts by weight: 30-60 parts of flurala self-micelle solid dispersion; 20 to 60 parts of a filling agent; 1-15 parts of a disintegrating agent; 1-5 parts of a lubricant; 1-5 parts of a flavoring agent; the fluralan self-micelle solid dispersion is prepared from the following components in parts by weight: 5-15 parts of fluralan, 1-5 parts of an emulsifier, 1-5 parts of a crosslinking agent, 1-5 parts of a crosslinking agent and the balance of water. 25 to 35 parts of a polyethylene caprolactam-polyvinyl acetate-polyethylene glycol grafted copolymer; 1 to 6 parts of a DSPE-PEG material modified by an RRRRRRRR peptide; and 1 to 6 parts of an ATS peptide modified DSPE-PEG material. The chewable tablet disclosed by the invention has the advantages of high drug dissolution rate, high oral bioavailability, half-life period of longfluralana and the like.

The invention discloses a medicine dissolution rate testing device which comprises a base placed on the ground, a heating box is fixedly connected to the base, a plurality of evenly-distributed hole grooves are formed in the heating box, and the inner wall of each hole groove is movably connected with a dissolution cup for testing the medicine dissolution rate. The outer contour, close to the end part, of each dissolution cup is fixedly connected with a limiting ring for supporting and placing the dissolution cup on the inner wall of the hole groove, and one side of the base is fixedly connected with a rectangular shell through an external bracket; a stirring mechanism for stirring a solution in the dissolution cup and a liquid pumping mechanism for detecting the dissolution rate of a medicine in the dissolution cup are arranged on the rectangular shell, the device has the advantages that the medicine solution in the dissolution cup is quantitatively pumped and detected, and the dissolution rate testing precision is improved.

The circulating stirring and dispensing device for mineral separation comprises a support and further comprises a body internally provided with a stirring assembly, a stirring barrel and a stirring motor. The stirring assembly comprises a first stirring rod, a second stirring rod and a stirring motor; the first stirring rod and the second stirring rod sleeve the rotating shaft from top to bottom; a rotating shaft at the bottom of the stirring barrel penetrates through the filter screen; the bottom of the body is provided with a pair of lead-out pipes with electromagnetic valves, the body is arranged on the support, mineral separation and medicine preparation can be circularly stirred, and the device has the advantages that different solid agents and liquid agents can be evenly mixed and stirred, the agents are rapidly dissolved, and a conveying pipeline cannot be blocked.

The present invention discloses a cyclopeptide glass and a pharmaceutical composition glass containing a cyclopeptide. The cyclopeptide glass of the present invention can simultaneously exert efficacy and function as a drug adjuvant. Compared with crystals and traditional drug dosage forms or adjuvants, the cyclopeptide glass effectively increases a drug dissolution rate, improves drug bioavailability, and may be widely used in the fields of drug delivery and sustained release for resistance to tumors, resistance to viruses / bacteria, blood sugar control, immune regulation, neuromodulation, etc.

The invention relates to the technical field of biodegradable materials, in particular to a polylactic acid microsphere with controllable degradation performance and a preparation method and application thereof. Comprising the following steps: S1, dissolving polylactic acid with the molecular weight of 50-200kDa in an organic solvent to obtain an oil phase, and dissolving a medicine in the solvent to obtain a water phase; s2, adding the water phase into the oil phase to form a W / O primary emulsion; s3, adding the W / O primary emulsion into a solution containing a surfactant with the mass volume concentration of 0.5%-2%, and stirring to form a W / O / W system; s4, performing solvent volatilization on the W / O / W system; and S5, collecting the microspheres, and drying. The particle size of the polylactic acid microspheres can be controlled, the high-quality polylactic acid microspheres with controllable degradation performance and drug release performance are prepared, and different biomedical application requirements are met.

The invention discloses a glucocorticoid-baicalein and / or baicalin co-amorphous substance and application thereof.The co-amorphous substance is formed by glucocorticoid, baicalein and / or baicalin in a non-covalent bond mode, the molar ratio of glucocorticoid to baicalein and / or baicalin is 1: 10-10: 1, powder X-ray diffraction analysis of CuK alpha radiation is adopted, and by taking 2 theta as the unit, the ratio of the glucocorticoid to the baicalein to the baicalein is 1: 10-1: 1. A powder X-ray diffraction pattern of the co-amorphous substance has a dispersion diffraction peak at a position of 15.0 + / -0.3 degrees to 27.0 + / -0.3 degrees. According to the application, glucocorticoid is combined with baicalein and / or baicalin according to a specific proportion, so that the pharmaceutical composition is used for treating or preventing thymoma. The composition is prepared by a mechanochemical method, forms a co-amorphous substance, and has the potential of improving the solubility of the medicine and improving the curative effect. Besides, the pharmaceutical composition can be prepared into various dosage forms, is convenient for clinical application, provides a new treatment choice for treating the thymoma, and particularly has remarkable clinical significance for patients with poor traditional treatment effects.

The invention provides a drug dissolution prediction method and device and electronic equipment, and the method comprises the steps: carrying out the feature extraction of near infrared spectrum data of a to-be-processed drug, and obtaining a spectrum feature; a machine learning model is utilized to predict the dissolution rate of the effective components in the medicine to be treated according to the spectral characteristics, and the machine learning model is constructed by extracting the spectral characteristics of the effective components according to the near infrared spectrum data of the sample medicine and the dissolution rates of the effective components in the sample medicine at different moments. In the implementation process of the scheme, the dissolution rate of the effective components in the to-be-treated medicine is predicted through the constructed machine learning model, the dissolution rate of the medicine can be obtained, the damage rate of a medicine sample is reduced, the method is suitable for detection of precious or special medicines, and through feature extraction and the machine learning model, the detection accuracy is improved. The requirements on complex equipment and medicine treatment are reduced, so that the dissolution rate of the medicine can be quickly predicted, and the detection efficiency is improved.

The application belongs to the technical field of drug dissolution and dispersion, and particularly relates to a bunazosin water-based solution preparation and a preparation method. The bunazosin water-based solution preparation provided by the application comprises the following components: bunazosin, gamma-cyclodextrin, lecithin, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, aspartame and water. The above components are mixed to be homogeneous to prepare an oral solution which is uniform, clear and can be stored for a long time. The scheme of the application further enriches the dosage form of bunazosin, improves the convenience of taking bunazosin, and is expected to help improve the oral bioavailability and absorption efficiency of bunazosin. The scheme of the application also provides a reference direction for the mechanism research on the dissolution and dispersion behavior of the insoluble bunazosin macromolecule in a water medium.

A method for improving drug solubility and a drug composite material having improved solubility. The method comprises preparing a silica colloidal suspension from silica nanoparticles having a diameter between 2 nm and 100 nm; rapidly evaporating a solvent by means of controlling the temperature and pressure, so as to obtain a porous surface material with ultra-high density silanol groups retained on the surface; and loading drug molecules. By controlling the size of nanoparticles and the density of silanol groups, drug molecules can be effectively adsorbed under anhydrous conditions, and rapidly desorbed and released in an aqueous environment.

The invention relates to the field of pharmaceutical preparations, and discloses a clopidogrel hydrogen sulfate tablet and a preparation method thereof, and the clopidogrel hydrogen sulfate tablet comprises the following components: 30-50 parts of clopidogrel hydrogen sulfate; 5-15 parts of a double-layer nano permeable membrane material; 3 to 12 parts of a pH sensitive release material; 5 to 12 parts of a supramolecular self-assembled nanoparticle material; 5 to 15 parts of a solubility regulator; 2-5 parts of an ionic crosslinking regulatory factor; 10 to 25 parts of an excipient; 0.5 to 2 parts of a lubricant; 0.5 to 2 parts of a stabilizer; the double-layer nano permeable membrane material comprises the following components in parts by weight: an inner layer material: 5-15 parts of hydroxypropyl # imgabs0 #-cyclodextrin; 3 to 10 parts of polyvinylpyrrolidone; an outer layer material: 2-8 parts of ethyl cellulose; and 2 to 10 parts of hydroxypropyl methylcellulose. The double-layer nano permeable membrane is combined with the pH-sensitive controlled release system, so that the dissolution rate of the medicine is adjustable, and accurate release in different pH environments is realized. The technical effects of improving the dissolution efficiency, optimizing medicine absorption and reducing individual differences are achieved.

The utility model discloses a pretreatment device for medicine inspection. The pretreatment device comprises a medicine dissolving tank, a filtering tank and a medicine dissolving solution collecting tank which are communicated with one another, the medicine dissolving tank is also communicated with a solvent storage tank; a stirring device is arranged in the medicine dissolving tank, the stirring device comprises a stirring shaft rotationally arranged in the medicine dissolving tank and a stirring motor connected with the stirring shaft, a plurality of crushing teeth are arranged on the stirring shaft, and the medicine dissolving tank is sleeved with a grinding cylinder on the outer side of the stirring device; a plurality of filtering holes are formed in the side wall of the grinding cylinder, a plurality of first grinding teeth are further arranged on the side wall of the grinding cylinder, and the first grinding teeth and the smashing teeth are arranged in a staggered mode; and an electric heating sheet is arranged in the solvent storage tank. The device can effectively grind and crush medicines, can also control the dissolving temperature, and greatly improves the crushing and grinding effect and dissolving efficiency of the medicines.

A pyridine amide compound-containing composition and a pharmaceutical composition, a preparation method therefor and a use thereof. The composition comprises an active ingredient and at least one matrix material, wherein the active ingredient is a compound represented by formula I or a pharmaceutically acceptable salt, a stereoisomer, a solvate, an isotopically labeled compound, a polymorph, a metabolite or a prodrug thereof. The composition has a high drug loading capacity, improves drug solubility, and has good stability. The in vivo bioavailability of the composition can reach the same level of bioavailability as that of a clear drug solution.

A glycoside drug oral preparation for treating cerebral ischemic stroke during the recovery period and a preparation method therefor. The glycoside drug is (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(4-(4-methoxyphenyl)butoxy)tetrahydro-2H-pyran-3,4,5-triol. The oral preparation can provide a high drug loading capacity, release the drug within a short time period, and ensure rapid drug dissolution, and the prepared tablet has high stability, involves a simple preparation process and is suitable for large-scale industrial production.

The present application belongs to the technical field of pharmaceutical preparations, and specifically provides a compound SYN045 soft capsule and a preparation method thereof. The present application adopts a fixed proportion of plant oil and polyoxyethylene glyceryl oleate combination to prepare the content, which helps to reduce the degradation of SYN045 in the content drug solution, ensures the stability of the active ingredient, and obtains a compound SYN045 soft capsule with good drug dissolution, high drug content, low impurity generation, and high bioavailability. Further, through prescription optimization of the soft capsule shell, a fixed proportion of plasticizer is selected, the mass ratio of glycerol and sorbitol is 1:2-3, the transfer of the compound SYN045 to the soft capsule shell is reduced, and thus the quality stability problem of the soft capsule preparation product during drug storage is solved.

The invention provides a drug dissolution degree detection method, system and equipment, a medium and a product. The detection method comprises the following steps: emitting target light into a container from the outside of the container and at a preset position; wherein a solution obtained after medicine is dissolved is stored in the container; acquiring target light intensity information of the solution in the container at each moment within a preset time; and obtaining medicine dissolution information in the container based on the target light intensity information corresponding to different moments. According to the method for detecting the dissolution degree of the medicine, the dissolution degree of the medicine in the container can be detected in time, automatically and accurately, human participation in judgment is not needed, and the use experience of a user is improved.

The application discloses a tripterine self-assembled nanoparticle microsphere, a preparation method and application thereof, and belongs to the technical field of biological medicines. The tripterine self-assembled nanoparticle microsphere takes tripterine self-assembled nanoparticles as a drug core, is formed by cross-linking of a sodium alginate-pectin composite carrier through calcium ions, can significantly improve drug solubility, realizes stable protection and intestinal targeting rapid release in the gastrointestinal tract, and effectively reduces drug systemic exposure and side effect risks. The preparation process is mild and simple, the obtained preparation has high targeting and safety. Pharmacodynamic results show that the microsphere can obviously improve liver steatosis, inflammation and fibrosis related to metabolic-related fatty liver hepatitis, and has better curative effect than conventional preparations. The application provides a novel oral delivery system for preventing and treating metabolic-related fatty liver hepatitis, and has good industrial and clinical transformation prospects.

This utility model relates to the field of wastewater treatment technology, specifically to a drug dissolving device for wastewater treatment. The device includes a dissolving cylinder, which comprises a cylinder body. A top cover is fixedly connected to the upper end of the cylinder body, and a bottom plate is fixedly connected to the lower end. The top cover is equipped with a stirring mechanism and a feeding mechanism for quantitatively adding drugs. The bottom plate is equipped with an air blowing mechanism for introducing air into the dissolving cylinder, and a sealing mechanism for sealing the dissolving cylinder is located below the bottom plate. A water pipe for adding water to the dissolving cylinder is installed on the side wall of the cylinder body, and an electrically controlled valve is installed on the water pipe. In this utility model, an air pump is used to pump external air into an annular and radial pipes, and then discharges it into the water through air outlets on the annular and radial pipes, creating surging bubbles in the water. Compared to simply having a stirring mechanism, this device further enhances water flow, thereby significantly increasing the drug dissolving speed.

The present application provides a drug-loaded microsphere for loading polypeptide drugs, the polypeptide drug delivery drug-loaded microsphere is W1 / O / W2 structure, which is composed of polypeptide drug active substance and hydrophilic gel as the inner water phase (W1), organic solvent of water-insoluble polymer as the oil phase (O), and solution containing emulsifier as the outer water phase (W2). The sustained-release microsphere of the present application introduces hydrophilic temperature-sensitive gel and water-insoluble polymer to co-load drugs, increases the hydrophilicity of the carrier, and reduces the solubility of polypeptide drugs by preparing metal ion-polypeptide drug active substance insoluble complex, thereby controlling the drug release behavior. Compared with the conventional microsphere, the sustained-release microsphere of the present application has the advantages of reducing drug burst release, shortening the drug release platform period, making the overall drug release behavior of the drug tend to zero-order release, releasing more stably, and improving the compliance of the microsphere preparation.

The present invention provides a furosemide solid preparation and a preparation method thereof, relating to the technical field of medicine. The solid preparation described in the present invention comprises the following components: furosemide, microenvironment pH regulator, preparation porosity regulator, diluent, disintegrant, lubricant. The microenvironment pH regulator is sodium bicarbonate, and the preparation porosity regulator is hydrophilic AEROSIL 200Pharma. In the present invention, porous AEROSIL 200Pharma is used to adsorb furosemide, and then sodium bicarbonate, the microenvironment pH regulator, is used to adjust the pH value of the saturated solution around the drug particles, which can improve the solubility of the drug and increase the drug dissolution.